LOCATIONS

CONTACT

Kansas City, Independence, Olathe, Shawnee, Leawood, Topeka, Lawrence, Emporia, Manhattan

DERMATOLOGY phone numbers and addresses

MEDSPA phone numbers and addresses 

KMC CAREERS

  • White Facebook Icon
  • YouTube - White Circle

© 2020 Kansas Medical Clinic, PA ​ - If you have a medical emergency, please call 911.  All information provided herein is for educational purposes only. If you have a medical condition, please consult a physician to get a proper diagnosis and treatment plan.

RESEARCH CENTER

CONTACT US

To learn more about how to be involved

in the clinical trials listed below

RESEARCH CENTER TEAM​

 

From right to left:

Principal Investigator, Shekhar Challa, MD

Clinical Research Staff, Susie Roeder

Sub-Investigator, Laura Welborn, APRN-C

Sub-Investigator, Balaji Datti, MD

 

For more information regarding all KMC clinical trials, please contact Susie Roeder at 785-295-0938. Call today!

KMC Research Center

2200 SW 6th Ave

Topeka KS 66606

 

KMC CURRENT CLINICAL TRIALS:

 

Non-Alcoholic Steatohepatitis (NASH)

Be part of new liver disease research!

 

The purpose of this study is to determine whether Cenicriviroc (CVC) is safe and effective in the treatment of non-alcoholic steatohepatitis/fatty liver disease (NASH) in adults with liver fibrosis.

Only 300 sites in the entire world are currently conducting this trial. Dr. Challa and KMC are honored to be participating!

 

 

The Corrona Registries 

Non-interventional Corrona Registry research programs are coordinated efforts to collect information directly from physicians and patients who are at least 18 years of age or older with an autoimmune disease, such as rheumatoid arthritis, psoriasis, psoriatic arthritis, spondylosing arthropathies, inflammatory bowel disease, and multiple sclerosis. 

 

Corrona has enrolled over 50,000 patients across the U.S. and Canada in the registries. Sites include a mix of academic, private, and hospital affiliated clinical practices. KMC is excited to be participating in this program!

 

 

Ulcerative Colitis

The present study (3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and endoscopy.

 

 

Crohn’s Disease

This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and endoscopy.

 

 

Clostridium Difficile (C-DIFF)

This study will evaluate efficacy and safety information about RBX2660 for the treatment of recurrent Clostridium difficile infection (CDI). Enrolled subjects will receive one treatment with RBX2660 (microbiota suspension).

 

 

Cirrhosis due to NASH

The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.

 

 

GERD

The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standard dose proton pump inhibitors (PPIs).

 

For more information regarding all KMC clinical trials, please contact Susie Roeder at 785-295-0938. Call today!